You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR ISTRADEFYLLINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for istradefylline

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00199355 ↗ A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa Completed Kyowa Hakko Kirin Company, Limited Phase 2 2005-04-01 To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
NCT00199355 ↗ A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa Completed Kyowa Kirin Co., Ltd. Phase 2 2005-04-01 To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
NCT00199368 ↗ An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 Completed Kyowa Hakko Kirin UK, Ltd. Phase 3 2004-10-01 This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199368 ↗ An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 Completed Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2004-10-01 This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199368 ↗ An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 Completed Kyowa Kirin, Inc. Phase 3 2004-10-01 This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
NCT00199381 ↗ An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001 Terminated Kyowa Kirin Pharmaceutical Development, Inc. Phase 3 2005-10-01 This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for istradefylline

Condition Name

Condition Name for istradefylline
Intervention Trials
Parkinson's Disease 16
Idiopathic Parkinson's Disease 2
Parkinson Disease 2
ALS 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for istradefylline
Intervention Trials
Parkinson Disease 20
Movement Disorders 1
Liver Diseases 1
Tremor 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for istradefylline

Trials by Country

Trials by Country for istradefylline
Location Trials
United States 54
Canada 6
Japan 5
Germany 2
Poland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for istradefylline
Location Trials
New Jersey 10
Massachusetts 3
Florida 3
Arizona 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for istradefylline

Clinical Trial Phase

Clinical Trial Phase for istradefylline
Clinical Trial Phase Trials
Phase 4 1
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for istradefylline
Clinical Trial Phase Trials
Completed 20
Not yet recruiting 3
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for istradefylline

Sponsor Name

Sponsor Name for istradefylline
Sponsor Trials
Kyowa Kirin, Inc. 11
Kyowa Kirin Pharmaceutical Development, Inc. 9
Kyowa Kirin Co., Ltd. 8
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for istradefylline
Sponsor Trials
Industry 37
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.